sorry I'm not well versed in how pharma acquisitions play out. can someone explain the potential pros and cons for proceeding to stage 3 trials self funded ($50m US cost), and partnering.
what does the share price do in both scenarios. not looking for price predictions, more timelines and potential cost differential as a round numbered multiplier based on success
Add to My Watchlist
What is My Watchlist?
